Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Discovery

• Publication date

  2013-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-12-0558PMID 23729478PMCID PMC4078408
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5)

  2013cited by this paper
• KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy

  2013cited by this paper
• Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

  2012cited by this paper
• Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

  2012cited by this paper
• Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion

  2012cited by this paper
• Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing

  2012cited by this paper
• Genetic heterogeneity and cancer drug resistance.

  2012cited by this paper
• Targeting MET in cancer: rationale and progress

  2012cited by this paper
• Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

  2012influential reference
• Targeting MET in cancer: rationale and progress

  2012cited by this paper
• Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

  2012cited by this paper
• Liver regeneration.

  2012cited by this paper
• Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

  2012cited by this paper
• The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

  2012cited by this paper
• Comprehensive molecular characterization of human colon and rectal cancer

  2012cited by this paper
• Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

  2012cited by this paper
• MET: a promising anticancer therapeutic target

  2012influential reference
• Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations

  2011cited by this paper
• MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

  2011cited by this paper
• Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

  2011cited by this paper
• Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

  2011cited by this paper
• Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing

  2011cited by this paper
• A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• MET signalling: principles and functions in development, organ regeneration and cancer

  2010cited by this paper
• Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

  2010cited by this paper
• Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing

  2010cited by this paper
• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

  2010cited by this paper
• Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

  2009cited by this paper
• Nuclear EGFR contributes to acquired resistance to cetuximab

  2009cited by this paper
• Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells

  2009cited by this paper
• HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

  2009cited by this paper
• MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

  2009cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

  2008cited by this paper
• Drug development of MET inhibitors: targeting oncogene addiction and expedience

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• EGFR antagonists in cancer treatment.

  2008cited by this paper
• A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.

  2008cited by this paper
• PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.

  2008cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

  2006cited by this paper
• Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.

  2005cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004influential reference
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists

  1999cited by this paper
• c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype.

  1998cited by this paper
• Liver Regeneration

  1997cited by this paper
• Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons.

  1997cited by this paper
• Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.

  1995cited by this paper
• Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET.

  1991cited by this paper
• A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer.

  1985cited by this paper

• Prognostic and predictive value of AXL and C-MET in patients with rectal cancer

  2026cites this paper
• Targeting the MAP kinase pathway in colorectal cancer: A journey in personalized medicine.

  2025cites this paper
• Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics

  2025cites this paper
• Lessons from a National Liquid Biopsy Program to Provide Cancer Testing and Treatment for Patients with Advanced Solid Tumors

  2025cites this paper
• The current landscape of neoadjuvant therapy for resectable colon cancer

  2025cites this paper
• Targeting drug resistant colorectal cancer with apigenin nanoarchitectures

  2025cites this paper
• Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment

  2025cites this paper
• Immunoinformatic analysis of role of tumor microenvironment constituents secreted ligands in breast cancer progression, metastasis, prognosis, survival and development of effective tumor microenvironment directed therapeutic strategy

  2025cites this paper
• Targeted Therapies Modulating Mesenchymal–Epithelial Transition-Linked Oncogenic Signaling in the Tumor Microenvironment: Comparative Profiling of Capmatinib, Bemcentinib, and Galunisertib

  2025cites this paper
• Overcoming NK cell resistance in triple-negative breast cancer via adcc with a humanized anti-CD147 antibody

  2025cites this paper
• Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance

  2025cites this paper
• Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers.

  2025cites this paper
• Evolving roles of MET as a therapeutic target in NSCLC and beyond

  2025cites this paper
• Targeting CAFs-Mediated Stromal Signaling in a Patient-Derived Organotypic Colorectal Tumor Model.

  2025cites this paper
• EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy

  2025cites this paper
• Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type

  2025cites this paper
• Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment

  2025cites this paper
• Natural products combating EGFR-TKIs resistance in cancer

  2025cites this paper
• Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

  2025cites this paper
• An overview of mechanisms, biomarkers, and treatment strategies for acquired anti-EGFR resistance in RAS wild-type colorectal cancer

  2025cites this paper
• RAB14-dependent tubulovesicular recycling directs MET to invadopodia, promoting TNBC cell invasion

  2025cites this paper
• Wuweizisu B for cancer treatment from multitarget mechanisms to precision delivery strategies (Review)

  2025cites this paper
• Response and Resistance to RAS Inhibition in Cancer.

  2025cites this paper
• Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology

  2025cites this paper
• Portrayal of the Complex Molecular Landscape of Multidrug Resistance in Gastric Cancer: Unveiling the Potential Targets.

  2025cites this paper
• Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions

  2025cites this paper
• Resistance to Allosteric Inhibitors.

  2025cites this paper
• Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions

  2025cites this paper
• MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies

  2025cites this paper
• Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer

  2024cites this paper
• Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

  2024cites this paper
• Bispecific antibody drug conjugates: Making 1+1>2

  2024cites this paper
• Virtual Screening, Molecular Dynamics Simulation, and Bioactivity Assessment Validate T13074 as a Dual-Target EGFR/c-Met Inhibitor.

  2024cites this paper
• Novel Near-Infrared Fluorescent Probe for Hepatocyte Growth Factor in Vivo Imaging in Surgical Navigation of Colorectal Cancer.

  2024cites this paper
• Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer

  2024cites this paper
• Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road

  2024cites this paper
• Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy

  2024cites this paper
• KRAS inhibitors: resistance drivers and combinatorial strategies.

  2024cites this paper
• Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review

  2024cites this paper
• A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer

  2024cites this paper
• The MET Oncogene Network of Interacting Cell Surface Proteins

  2024cites this paper
• The MET Oncogene: An Update on Targeting Strategies

  2024cites this paper
• First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?

  2024cites this paper
• HOXB8 mediates resistance to cetuximab in colorectal cancer cells through activation of the STAT3 pathway

  2024cites this paper
• Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer

  2024cites this paper
• Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance

  2024cites this paper
• CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration

  2024cites this paper
• The Roles of RAC1 and RAC1B in Colorectal Cancer and Their Potential Contribution to Cetuximab Resistance

  2024cites this paper
• Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells

  2024cites this paper
• Consistency between Primary Uterine Corpus Malignancies and Their Corresponding Patient-Derived Xenograft Models

  2024cites this paper
• The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy

  2024cites this paper
• Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data

  2024cites this paper
• Switching anti-EGFR antibody re-sensitizes head and neck cancer patient following acquired resistance to cetuximab

  2024cites this paper
• Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer

  2024cites this paper
• Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling

  2024cites this paper
• The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review.

  2024cites this paper
• Unveiling promising targets in gastric cancer therapy: A comprehensive review

  2024cites this paper
• MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature

  2024cites this paper
• An Observatory for the MET Oncogene: A Guide for Targeted Therapies

  2023cites this paper
• Translational research of new developments in targeted therapy of colorectal cancer.

  2023cites this paper
• An mTOR feedback loop mediates the ‘flare’ (‘rebound’) response to MET tyrosine kinase inhibition

  2023cites this paper
• Overcoming the hurdles: surmounting acquired resistance to anti-EGFR therapy in metastatic colorectal cancer.

  2023cites this paper
• MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities

  2023cites this paper
• Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer

  2023influential citation
• Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report

  2023cites this paper
• Liquid biopsy in colorectal cancer: onward and upward.

  2023cites this paper
• Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer

  2023cites this paper
• Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer

  2023cites this paper
• Liquid Biopsy in Advanced Colorectal Cancer: Clinical Applications of Different Analytes

  2023cites this paper
• Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer

  2023cites this paper
• Overview of the role of liquid biopsy in cancer management

  2023cites this paper
• Advancements in Focal Amplification Detection in Tumor/Liquid Biopsies and Emerging Clinical Applications

  2023cites this paper
• Clinical application of circulating tumour DNA in colorectal cancer.

  2023cites this paper
• Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance

  2023cites this paper
• A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial

  2023cites this paper
• The functional and clinical roles of liquid biopsy in patient-derived models

  2023cites this paper
• Mutational evolution after chemotherapy‐progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis

  2023cites this paper
• Sequence-Based Platforms for Discovering Biomarkers in Liquid Biopsy of Non-Small-Cell Lung Cancer

  2023cites this paper
• Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments

  2023cites this paper
• Crizotinib‐based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation

  2023cites this paper
• Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation

  2023cites this paper
• Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer

  2023cites this paper
• Correction: An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies

  2023cites this paper
• A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

  2023cites this paper
• Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-specific Transcriptome and Molecular Subtype

  2023cites this paper
• Effect of Food on the Pharmacokinetics and Safety of a Novel c-Met Inhibitor SCC244: A Randomized Phase I Study in Healthy Subjects

  2023cites this paper
• Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials

  2023cites this paper
• The HER family as therapeutic targets in colorectal cancer.

  2022cites this paper
• hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers

  2022cites this paper
• Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor–Amplified Gastroesophageal Cancer: Retrospective Global Experience

  2022cites this paper
• Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer

  2022influential citation
• SERS characterization of colorectal cancer cell surface markers upon anti‐EGFR treatment

  2022cites this paper
• The Occurrence of MET Ectodomain Shedding in Oral Cancer and Its Potential Impact on the Use of Targeted Therapies

  2022cites this paper
• Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.

  2022cites this paper
• Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers

  2022cites this paper
• Predictive “omic” biomarkers of drug response: Colorectal cancer as a model

  2022cites this paper
• Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors

  2022cites this paper
• Use of Cabozantinib to Treat MET-amplified Pediatric Colorectal Cancer.

  2022cites this paper
• Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse

  2022cites this paper
• Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment

  2022cites this paper